InMode (NASDAQ:INMD – Get Free Report) and Allurion Technologies (NYSE:ALUR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for InMode and Allurion Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| InMode | 1 | 7 | 1 | 0 | 2.00 |
| Allurion Technologies | 1 | 2 | 1 | 0 | 2.00 |
InMode currently has a consensus target price of $16.80, indicating a potential upside of 17.48%. Allurion Technologies has a consensus target price of $9.25, indicating a potential upside of 714.98%. Given Allurion Technologies’ higher possible upside, analysts plainly believe Allurion Technologies is more favorable than InMode.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| InMode | $370.49 million | 2.45 | $93.83 million | $1.44 | 9.93 |
| Allurion Technologies | $32.11 million | 0.43 | -$7.20 million | ($10.56) | -0.11 |
InMode has higher revenue and earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares InMode and Allurion Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| InMode | 25.33% | 14.52% | 12.88% |
| Allurion Technologies | -199.96% | N/A | -77.13% |
Volatility & Risk
InMode has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, Allurion Technologies has a beta of -0.43, suggesting that its stock price is 143% less volatile than the S&P 500.
Insider and Institutional Ownership
68.0% of InMode shares are held by institutional investors. Comparatively, 21.4% of Allurion Technologies shares are held by institutional investors. 6.9% of InMode shares are held by company insiders. Comparatively, 8.1% of Allurion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
InMode beats Allurion Technologies on 10 of the 12 factors compared between the two stocks.
About InMode
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
About Allurion Technologies
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.
